Unmet need in lung cancer: Can vaccines bridge the gap?

Clinical Lung Cancer

Volumn 9, Issue SUPPL. 1, 2008, Pages

  Kim, Jae ^a   Raz, Dan ^a   Jablons, David ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Dendritic cells; GM CSF; MAGE A3; MUC1; Tumor antigens

Indexed keywords

BCG VACCINE; CANCER VACCINE; DENDRITIC CELL VACCINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR VACCINE; MONOCLONAL ANTIBODY; TUMOR ANTIGEN;

ANTIGEN PRESENTING CELL; CANCER IMMUNIZATION; CANCER IMMUNOLOGY; CANCER IMMUNOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; CYTOTOXIC T LYMPHOCYTE; DNA MODIFICATION; GENE EXPRESSION; HUMAN; IMMUNE RESPONSE; IMMUNOSTIMULATION; IMMUNOSURVEILLANCE; LUNG CANCER; LUNG NON SMALL CELL CANCER; LUNG RESECTION; REVIEW; SURVIVAL RATE; T LYMPHOCYTE ACTIVATION; TREATMENT OUTCOME; TUMOR CELL;

EID: 40449114433     PISSN: 15257304     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLC.2008.s.002     Document Type: Article

References (67)

1. DM Parkin F Bray J Ferlay Global cancer statistics, 2002 CA Cancer J Clin 55 2005 74 108
2. A Jemal R Siegel E Ward Cancer statistics, 2007 CA Cancer J Clin 57 2007 43 66
3. FA Shepherd J Rodrigues Pereira T Ciuleanu Erlotinib in previously treated non-small-cell lung cancer N Engl J Med 353 2005 123 132
4. G Giaccone RS Herbst C Manegold Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial– INTACT 1 J Clin Oncol 22 2004 777 784
5. RS Herbst D Prager R Hermann TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer J Clin Oncol 23 2005 5892 5899
6. WB Coley The treatment of malignant tumors by repeated inoculations of erysipelas. With a report of ten original cases. 1893 Clin Orthop Relat Res 262 1991 3 11
7. S Feng JF Buell RS Chari Tumors and transplantation: The 2003 Third Annual ASTS State-of-the-Art Winter Symposium Am J Transplant 3 2003 1481 1487
8. HM Kauffman Malignancies in organ transplant recipients J Surg Oncol 94 2006 431 433
9. V Shankaran H Ikeda AT Bruce IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity Nature 410 2001 1107 1111
10. O Wakabayashi K Yamazaki S Oizumi CD4+ T cells in cancer stroma, not CD8+ T cells in cancer cell nests, are associated with favorable prognosis in human non-small cell lung cancers Cancer Sci 94 2003 1003 1009
11. PW Miller S Sharma M Stolina Intratumoral administration of adenoviral interleukin 7 gene-modified dendritic cells augments specific antitumor immunity and achieves tumor eradication Hum Gene Ther 11 2000 53 65
12. L Novellino C Castelli G Parmiani A listing of human tumor antigens recognized by T cells: March 2004 update Cancer Immunol Immunother 54 2005 187 207
13. D Atanackovic NK Altorki E Stockert Vaccine-induced CD4+ T cell responses to MAGE-3 protein in lung cancer patients J Immunol 172 2004 3289 3296
14. MN Dickler G Ragupathi NX Liu Immunogenicity of a fucosyl-GM1-keyhole limpet hemocyanin conjugate vaccine in patients with small cell lung cancer Clin Cancer Res 5 1999 2773 2779
15. G Gonzalez T Crombet E Neninger Therapeutic vaccination with epidermal growth factor (EGF) in advanced lung cancer: analysis of pooled data from three clinical trials Hum Vaccin 3 2007 8 13
16. LM Krug G Ragupathi C Hood Vaccination of patients with small-cell lung cancer with synthetic fucosyl GM-1 conjugated to keyhole limpet hemocyanin Clin Cancer Res 10 2004 6094 6100
17. Y Oka A Tsuboi T Taguchi Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression Proc Natl Acad Sci U S A 101 2004 13885 13890
18. LG Salazar J Fikes S Southwood Immunization of cancer patients with HER-2/neu-derived peptides demonstrating high-affinity binding to multiple class II alleles Clin Cancer Res 9 2003 5559 5565
19. A Sandler R Gray MC Perry Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer N Engl J Med 355 2006 2542 2550
20. MJ Piccart-Gebhart M Procter B Leyland-Jones Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer N Engl J Med 353 2005 1659 1672
21. GA Leget MS Czuczman Use of rituximab, the new FDA-approved antibody Curr Opin Oncol 10 1998 548 551
22. D Cunningham Y Humblet S Siena Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer N Engl J Med 351 2004 337 345
23. P Campbell R Marcus Monoclonal antibody therapy for lymphoma Blood Rev 17 2003 143 152
24. OJ Finn Cancer vaccines: between the idea and the reality Nat Rev Immunol 3 2003 630 641
25. SO Ryan KR Gantt OJ Finn Tumor antigen-based immunotherapy and immunoprevention of cancer Int Arch Allergy Immunol 142 2007 179 189
26. D Pardoll Does the immune system see tumors as foreign or self? Annu Rev Immunol 21 2003 807 839
27. AT Stopeck A Gessner TP Miller Loss of B7.2 (CD86) and intracellular adhesion molecule 1 (CD54) expression is associated with decreased tumor-infiltrating T lymphocytes in diffuse B-cell large-cell lymphoma Clin Cancer Res 6 2000 3904 3909
28. DM Dorfman JL Schultze A Shahsafaei In vivo expression of B7-1 and B7-2 by follicular lymphoma cells can prevent induction of T-cell anergy but is insufficient to induce significant T-cell proliferation Blood 90 1997 4297 4306
29. B He RN Barg L You Wnt signaling in stem cells and non-small-cell lung cancer Clin Lung Cancer 7 2005 54 60
30. J Marx Cancer research. Mutant stem cells may seed cancer Science 301 2003 1308 1310
31. ML Garcia-Hernandez R Hernandez-Pando P Gariglio Interleukin-10 promotes B16-melanoma growth by inhibition of macrophage functions and induction of tumour and vascular cell proliferation Immunology 105 2002 231 243
32. BF Skinnider TW Mak The role of cytokines in classical Hodgkin lymphoma Blood 99 2002 4283 4297
33. JM Wroblewski DL Bixby C Borowski Characterization of human nonsmall cell lung cancer (NSCLC) cell lines for expression of MHC, co-stimulatory molecules and tumor-associated antigens Lung Cancer 33 2001 181 194
34. K Tajima Y Obata H Tamaki Expression of cancer/testis (CT) antigens in lung cancer Lung Cancer 42 2003 23 33
35. CR Lockyer DA Gillatt BCG immunotherapy for superficial bladder cancer J R Soc Med 94 2001 119 123
36. K Yasumoto H Manabe E Yanagawa Nonspecific adjuvant immunotherapy of lung cancer with cell wall skeleton of Mycobacterium bovis Bacillus Calmette-Guerin Cancer Res 39 1979 3262 3267
37. Y Yamamura M Sakatani T Ogura Adjuvant immunotherapy of lung cancer with BCG cell wall skeleton (BCG-CWS) Cancer 43 1979 1314 1319
38. MH Gail A placebo-controlled randomized double-blind study of adjuvant intrapleural BCG in patients with resected T1N0, T1N1, or T2N0 squamous cell carcinoma, adenocarcinoma, or large cell carcinoma of the lung. LCSG Protocol 771 Chest 106 1994 287S 292S
39. ME O'Brien H Anderson E Kaukel SRL172 (killed Mycobacterium vaccae) in addition to standard chemotherapy improves quality of life without affecting survival, in patients with advanced non-small-cell lung cancer: phase III results Ann Oncol 15 2004 906 914
40. B Spies H Hochrein M Vabulas Vaccination with plasmid DNA activates dendritic cells via Toll-like receptor 9 (TLR9) but functions in TLR9-deficient mice J Immunol 171 2003 5908 5912
41. RS Schulof D Mai MA Nelson Active specific immunotherapy with an autologous tumor cell vaccine in patients with resected non-small cell lung cancer Mol Biother 1 1988 30 36
42. R Salgia T Lynch A Skarin Vaccination with irradiated autologous tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor augments antitumor immunity in some patients with metastatic non-small-cell lung carcinoma J Clin Oncol 21 2003 624 630
43. J Nemunaitis RO Dillman PO Schwarzenberger Phase II study of belagenpumatucel-L, a transforming growth factor beta-2 antisense gene-modified allogeneic tumor cell vaccine in non-small-cell lung cancer J Clin Oncol 24 2006 4721 4730
44. J Nemunaitis T Jahan H Ross Phase 1/2 trial of autologous tumor mixed with an allogeneic GVAX vaccine in advanced-stage non-small-cell lung cancer Cancer Gene Ther 13 2006 555 562
45. LE Raez PA Cassileth JJ Schlesselman Allogeneic vaccination with a B7.1 HLA-A gene-modified adenocarcinoma cell line in patients with advanced nonsmall-cell lung cancer J Clin Oncol 22 2004 2800 2807
46. J Vansteenkiste M Zielinksi A Linder Activity of MAGE-A3 cancer immunotherapeutic as adjuvant therapy in stage IB/II non-small cell lung cancer (NSCLC): final results of a multi-center, double-blind, randomized, placebo-controlled phase II study: B1-05 Journal of Thoracic Oncology 2 2007 S334 S335
47. G Giaccone C Debruyne E Felip Phase III study of adjuvant vaccination with Bec2/bacille Calmette-Guerin in responding patients with limited-disease small-cell lung cancer (European Organisation for Research and Treatment of Cancer 08971-08971B; Silva Study) J Clin Oncol 23 2005 6854 6864
48. C Butts N Murray A Maksymiuk Randomized phase IIB trial of BLP25 liposome vaccine in stage IIIB and IV non-small-cell lung cancer J Clin Oncol 23 2005 6674 6681
49. C Rochlitz R Figlin P Squiban Phase I immunotherapy with a modified vaccinia virus (MVA) expressing human MUC1 as antigen-specific immunotherapy in patients with MUC1-positive advanced cancer J Gene Med 5 2003 690 699
50. H Horig DS Lee W Conkright Phase I clinical trial of a recombinant canarypoxvirus (ALVAC) vaccine expressing human carcinoembryonic antigen and the B7.1 co-stimulatory molecule Cancer Immunol Immunother 49 2000 504 514
51. T Brezicka B Bergman S Olling Reactivity of monoclonal antibodies with ganglioside antigens in human small cell lung cancer tissues Lung Cancer 28 2000 29 36
52. SC Grant MG Kris AN Houghton Long survival of patients with small cell lung cancer after adjuvant treatment with the anti-idiotypic antibody BEC2 plus Bacillus Calmette-Guerin Clin Cancer Res 5 1999 1319 1323
53. SB Ho GA Niehans C Lyftogt Heterogeneity of mucin gene expression in normal and neoplastic tissues Cancer Res 53 1993 641 651
54. J Babatz C Rollig B Lobel Induction of cellular immune responses against carcinoembryonic antigen in patients with metastatic tumors after vaccination with altered peptide ligand-loaded dendritic cells Cancer Immunol Immunother 55 2006 268 276
55. L Fong Y Hou A Rivas Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy Proc Natl Acad Sci U S A 98 2001 8809 8814
56. T Itoh Y Ueda I Kawashima Immunotherapy of solid cancer using dendritic cells pulsed with the HLA-A24-restricted peptide of carcinoembryonic antigen Cancer Immunol Immunother 51 2002 99 106
57. MA Morse TM Clay AC Hobeika Phase I study of immunization with dendritic cells modified with fowlpox encoding carcinoembryonic antigen and costimulatory molecules Clin Cancer Res 11 2005 3017 3024
58. MA Morse Y Deng D Coleman A Phase I study of active immunotherapy with carcinoembryonic antigen peptide (CAP-1)-pulsed, autologous human cultured dendritic cells in patients with metastatic malignancies expressing carcinoembryonic antigen Clin Cancer Res 5 1999 1331 1338
59. Y Ueda T Itoh I Nukaya Dendritic cell-based immunotherapy of cancer with carcinoembryonic antigen-derived, HLA-A24-restricted CTL epitope: Clinical outcomes of 18 patients with metastatic gastrointestinal or lung adenocarcinomas Int J Oncol 24 2004 909 917
60. SK Nair M Morse D Boczkowski Induction of tumor-specific cytotoxic T lymphocytes in cancer patients by autologous tumor RNA-transfected dendritic cells Ann Surg 235 2002 540 549
61. MA Morse SK Nair PJ Mosca Immunotherapy with autologous, human dendritic cells transfected with carcinoembryonic antigen mRNA Cancer Invest 21 2003 341 349
62. K Kontani O Taguchi Y Ozaki Dendritic cell vaccine immunotherapy of cancer targeting MUC1 mucin Int J Mol Med 12 2003 493 502
63. EA Hirschowitz T Foody R Kryscio Autologous dendritic cell vaccines fornon-small-cell lung cancer J Clin Oncol 22 2004 2808 2815
64. P Hersey AS Coates WH McCarthy Adjuvant immunotherapy of patientswith high-risk melanoma using vaccinia viral lysates of melanoma: results of a randomized trial J Clin Oncol 20 2002 4181 4190
65. VK Sondak PY Liu RJ Tuthill Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: overall results of a randomized trial of the Southwest Oncology Group J Clin Oncol 20 2002 2058 2066
66. JE Harris L Ryan HC Hoover Jr Adjuvant active specific immunotherapy for stage II and III colon cancer with an autologous tumor cell vaccine: Eastern Cooperative Oncology Group Study E5283 J Clin Oncol 18 2000 148 157
67. AG Dalgleish MA Whelan Cancer vaccines as a therapeutic modality: the long trek Cancer Immunol Immunother 55 2006 1025 1032